TT 00973
Alternative Names: TT-00973; TT-00973-MSLatest Information Update: 04 Sep 2025
At a glance
- Originator TransThera Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 30 May 2025 Phase-I clinical trials in Solid tumours (Late-stage disease; Second-line therapy or greater) in China (PO) prior to May 2025 (NCT05673538)
- 30 May 2025 Efficacy, pharmacodynamic and adverse events data from a phase I trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 12 Jan 2023 Preclinical trials in Acute myeloid leukaemia in China (PO) before January 2023 (TransThera Biosciences pipeline, January 2023)